Study on Pembrolizumab With or Without V940 for Non-Small Cell Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that can be surgically removed and is at Stage II, IIIA, or IIIB (N2).
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have not achieved a complete response to chemotherapy and pembrolizumab before surgery.
• Do not require treatment targeting specific EGFR mutations.
• If HIV-positive, have well-controlled HIV on anti-retroviral therapy.
• If hepatitis B positive, have been on antiviral therapy for at least 4 weeks with undetectable viral load.
• If previously infected with hepatitis C, have an undetectable viral load at screening.

Exclusion Criteria

• Have a diagnosis of small cell lung cancer or certain other types of lung tumors.
• Have a specific gene rearrangement known as ALK.
• Have received prior neoadjuvant therapy for the current lung cancer diagnosis.
• Have previously been treated with certain immune therapies targeting PD-1, PD-L1, or similar pathways.
• Have received other systemic cancer treatments not specified in this study.
• Have been treated with a cancer vaccine before.
• Have had recent radiotherapy within 2 weeks before starting the study treatment or have radiation-related side effects requiring steroids.
• Have received a live vaccine within 30 days before starting the study treatment.